`
`
`
`FORM 26. Docketing Statement
`
`Form 26 (p. 1)
`July 2020
`
`UNITED STATES COURT OF APPEALS
`
`FOR THE FEDERAL CIRCUIT
`
`
`
`AMENDED DOCKETING STATEMENT
`
`Case Number:
`
`Short Case Caption:
`
`Filing Party/Entity:
`
`------------------------
`
`Instructions:
`Complete each section or check the box if a section is intentionally
`
`
`
`
`
`
`blank or not applicable. Attach additional pages as needed. Refer to the court's
`
`
`
`
`Mediation Guidelines for filing requirements. An amended docketing statement is
`
`
`
`required for each new appeal or cross-appeal consolidated after first filing.
`
`
`
`Case Origin Originating Number
`
`Type of Case
`
`
`
`Applicable Relief sought on appeal: D None/Not
`
`
`
`
`
`
`
`Relief awarded below (if damages, specify):
`
`D None/Not Applicable
`
`
`
`
`
`Briefly describe the judgment/order appealed from:
`
`
`
`
`
`
`
`
`
`
`
`Nature of judgment (select one): Date of judgment: ______ _
`
`D Final Judgment, 28 USC § 1295
`
`D Rule 54(b)
`
`
`D Other ( explain)
`
`D Interlocutory Order (specify type)--------------
`
`2022-1595; 2022-1714
`
`Genentech, Inc. v. Sandoz Inc.
`
`Genentech, Inc. and InterMune, Inc.
`
`U.S. Dist. Ct., Delaware
`
`19-78 (RGA)
`
`Patent Infringement - ANDA
`
`Reversal or vacatur of judgment of non-infringement and invalidity regarding four
`asserted patents; affirmance of judgment of validity regarding two asserted patents.
`
`None
`
`Judgment of non-infringement of each of six asserted patents, invalidity of four patents due to obviousness, validity
`of two patents, where the patents relate to Genentech's Esbriet (pirfenidone) and Defendants' infringement due to
`ANDAs relating to generic versions of same.
`
`4
`
`4/1/22
`
`
`
`Case: 22-1595 Document: 20 Page: 2 Filed: 05/09/2022
`
`4
`
`Whether the district court erred in finding non-infringement of all six asserted patents. Whether the district court erred in finding
`invalidity of four of six asserted patents. Whether the district court was correct in finding validity of two asserted patents.
`
`4
`
`N/A
`
`4
`
`The parties have argued their respective positions, which are unlikely to change
`
`Kira A. Davis
`
`5/9/22
`
`/s/ Kira A. Davis
`
`4
`
`N/A
`
`4
`
`